Get the Stockscreener App
5.39
2.28%
0.12
After Hours:
5.39
Foghorn Therapeutics Inc stock is traded at $5.39, with a volume of 37,319.
It is up +2.28% in the last 24 hours and up +4.86% over the past month.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
See More
Previous Close:
$5.27
Open:
$5.29
24h Volume:
37,319
Relative Volume:
0.32
Market Cap:
$304.70M
Revenue:
$34.16M
Net Income/Loss:
$-98.43M
P/E Ratio:
-2.3034
EPS:
-2.34
Net Cash Flow:
$-119.33M
1W Performance:
+7.58%
1M Performance:
+4.86%
6M Performance:
+22.78%
1Y Performance:
-32.37%
1-Day Range:
$5.14
$5.40
1-Week Range:
$4.90
$5.4573
52-Week Range:
$2.9448
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Name
Foghorn Therapeutics Inc
Sector
Industry
Phone
617-586-3100
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
5.39 | 298.48M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-30-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-24 | Initiated | Jefferies | Buy |
| Aug-19-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-23 | Initiated | BofA Securities | Buy |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-22-21 | Initiated | H.C. Wainwright | Buy |
| Nov-17-20 | Initiated | Cowen | Outperform |
| Nov-17-20 | Initiated | Goldman | Buy |
| Nov-17-20 | Initiated | Morgan Stanley | Overweight |
| Nov-17-20 | Initiated | Wedbush | Outperform |
View All
Foghorn Therapeutics Inc Stock (FHTX) Latest News
Does Foghorn Therapeutics Inc. have high return on assetsJuly 2025 Movers & AI Enhanced Execution Alerts - khodrobank.com
What’s the analyst consensus on Foghorn Therapeutics Inc.Rate Hike & Daily Profit Focused Screening - khodrobank.com
Is Foghorn Therapeutics Inc. a speculative investmentEarnings Recap Summary & Weekly High Potential Stock Alerts - khodrobank.com
Is Foghorn Therapeutics Inc. trending in predictive chart modelsMarket Performance Recap & AI Optimized Trading Strategy Guides - Newser
How to build a custom watchlist for Foghorn Therapeutics Inc.2025 Big Picture & High Conviction Buy Zone Picks - Newser
Foghorn Therapeutics Inc. stock prediction for this weekAnalyst Downgrade & Smart Allocation Stock Tips - Newser
What the charts say about Foghorn Therapeutics Inc. todayExit Point & Reliable Price Breakout Alerts - Newser
Value Recap: Does Foghorn Therapeutics Inc. stock benefit from AI growthJuly 2025 Momentum & Weekly Watchlist for Consistent Profits - khodrobank.com
Price action breakdown for Foghorn Therapeutics Inc.July 2025 Breakouts & Technical Buy Zone Confirmations - Newser
Does Foghorn Therapeutics Inc. stock benefit from AI growth2025 Trade Ideas & Weekly Market Pulse Updates - khodrobank.com
Backtesting results for Foghorn Therapeutics Inc. trading strategiesQuarterly Earnings Report & Expert Approved Momentum Trade Ideas - Newser
Trend analysis for Foghorn Therapeutics Inc. this week2025 Key Lessons & Safe Investment Capital Preservation Plans - Newser
How did FHTX's Q4 2024 earnings surprise impact investor confidence? - AInvest
What earnings revisions data tells us about Foghorn Therapeutics IncEarnings Risk Report & AI Forecast Swing Trade Picks - Newser
What earnings revisions data tells us about Foghorn Therapeutics Inc.Weekly Trend Report & Proven Capital Preservation Tips - Newser
AI Indicators Detect Buy Opportunity in Foghorn Therapeutics Inc.July 2025 Movers & Technical Confirmation Alerts - beatles.ru
Combining price and volume data for Foghorn Therapeutics Inc.Market Performance Summary & Precise Swing Trade Alerts - Newser
Heatmap analysis for Foghorn Therapeutics Inc. and competitors2025 Market Overview & Free Accurate Trade Setup Notifications - Newser
Foghorn Therapeutics Advances in Precision Therapeutics - TipRanks
Using RSI to spot recovery in Foghorn Therapeutics Inc.2025 Market Sentiment & Smart Investment Allocation Tips - Newser
Has Foghorn Therapeutics Inc. found a price floorQuarterly Trade Summary & Daily Entry Point Alerts - Newser
Is Foghorn Therapeutics Inc. a good ESG investmentJuly 2025 Price Swings & Low Drawdown Trading Strategies - khodrobank.com
Uveal Melanoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Novartis, Foghorn Therapeutics Inc., TriSalus Life Sciences, Inc., AstraZeneca - The Globe and Mail
Does Foghorn Therapeutics Inc. have pricing powerLayoff News & Technical Buy Zone Confirmation - khodrobank.com
How to track smart money flows in Foghorn Therapeutics Inc.Weekly Investment Recap & Free Growth Oriented Trading Recommendations - Newser
Foghorn Therapeutics Inc. stock trend forecastPortfolio Value Report & Safe Entry Momentum Tips - Newser
When is the best time to exit Foghorn Therapeutics Inc.July 2025 Volume & Fast Exit and Entry Strategy Plans - Newser
Is Foghorn Therapeutics Inc. vulnerable to short sellers2025 Price Momentum & Stepwise Entry/Exit Trade Alerts - khodrobank.com
Can Foghorn Therapeutics Inc. expand into new marketsJuly 2025 Rallies & AI Enhanced Execution Alerts - khodrobank.com
Ranking Foghorn Therapeutics Inc. among high performing stocks via toolsJuly 2025 Catalysts & Weekly Momentum Picks - Newser
Can Foghorn Therapeutics Inc. stock double in the next yearWeekly Stock Recap & Expert Approved Trade Ideas - khodrobank.com
Wall Street Analysts Predict a 130.63% Upside in Foghorn Therapeutics (FHTX): Here's What You Should Know - Yahoo Finance
Real time social sentiment graph for Foghorn Therapeutics Inc.Earnings Summary Report & High Yield Equity Trading Tips - Newser
Predicting Foghorn Therapeutics Inc. trend using moving averages2025 Sector Review & Proven Capital Preservation Methods - Newser
How sentiment analysis helps forecast Foghorn Therapeutics Inc.July 2025 Spike Watch & Community Consensus Trade Signals - Newser
Does Foghorn Therapeutics Inc. fit your quant trading modelRate Cut & Weekly High Potential Stock Alerts - Newser
Foghorn Therapeutics Inc. stock outlook for YEARQuarterly Profit Report & Reliable Trade Execution Plans - Newser
Forecasting Foghorn Therapeutics Inc. price range with options data2025 Price Targets & Long-Term Capital Growth Strategies - Newser
Real time pattern detection on Foghorn Therapeutics Inc. stockDay Trade & Real-Time Market Trend Scan - Newser
Will earnings trigger a reversal in Foghorn Therapeutics Inc.2025 Retail Activity & Accurate Buy Signal Notifications - Newser
Foghorn Therapeutics Inc Stock (FHTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Foghorn Therapeutics Inc Stock (FHTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Costa Carlos | Chief People Officer |
Sep 23 '24 |
Option Exercise |
3.72 |
857 |
3,188 |
857 |
| Costa Carlos | Chief People Officer |
Sep 20 '24 |
Sale |
10.04 |
35,756 |
358,990 |
0 |
| Costa Carlos | Chief People Officer |
Sep 23 '24 |
Sale |
10.17 |
857 |
8,716 |
0 |
| Costa Carlos | Chief People Officer |
Sep 18 '24 |
Option Exercise |
3.72 |
11,574 |
43,055 |
11,574 |
| Costa Carlos | Chief People Officer |
Sep 18 '24 |
Sale |
10.05 |
11,574 |
116,319 |
0 |
| Costa Carlos | Chief People Officer |
Sep 17 '24 |
Option Exercise |
3.72 |
10,272 |
38,212 |
10,272 |
| Costa Carlos | Chief People Officer |
Sep 16 '24 |
Option Exercise |
3.72 |
400 |
1,488 |
400 |
| Costa Carlos | Chief People Officer |
Sep 17 '24 |
Sale |
10.04 |
10,272 |
103,131 |
0 |
| Costa Carlos | Chief People Officer |
Sep 16 '24 |
Sale |
10.00 |
400 |
4,000 |
0 |
1.75%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):